Does ertapenem provide coverage against carbapenem‑resistant Klebsiella pneumoniae and Enterococcus species?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No, ertapenem does NOT provide coverage against carbapenem-resistant Klebsiella pneumoniae or Enterococcus species

Ertapenem is completely ineffective against carbapenem-resistant organisms and has no activity against Enterococcus species, even when they are carbapenem-susceptible. This is a critical distinction that must be understood to avoid treatment failure and increased mortality.

Why Ertapenem Fails Against These Organisms

Carbapenem-Resistant Klebsiella pneumoniae (CRKP)

Ertapenem is hydrolyzed by carbapenemases, the enzymes that confer carbapenem resistance 1. When K. pneumoniae develops carbapenem resistance through mechanisms like:

  • KPC (Klebsiella pneumoniae carbapenemase) - the most common type
  • MBLs (metallo-β-lactamases) like NDM, VIM, IMP
  • OXA-48-like enzymes

These enzymes rapidly degrade ertapenem, rendering it completely ineffective 2. In fact, ertapenem resistance often emerges before resistance to other carbapenems (imipenem/meropenem) because ertapenem has higher affinity for carbapenemases and is more easily hydrolyzed 3.

For carbapenem-resistant K. pneumoniae, the recommended first-line agents are:

  • Ceftazidime-avibactam (for KPC-producers)
  • Meropenem-vaborbactam (for KPC-producers)
  • Imipenem-relebactam or cefiderocol as alternatives 2

Enterococcus Species

Ertapenem has NO intrinsic activity against Enterococcus species - this is a fundamental spectrum limitation 1, 4. The FDA label explicitly excludes Enterococcus from ertapenem's coverage 1. This is true regardless of whether the Enterococcus is vancomycin-susceptible or vancomycin-resistant.

For Enterococcus infections, appropriate agents include:

  • Linezolid 600 mg IV/PO q12h (strong recommendation for enterococcal infections) 5
  • High-dose daptomycin 8-12 mg/kg IV daily ± β-lactams for VRE bacteremia 5
  • Ampicillin or amoxicillin for susceptible strains 5

Ertapenem's Actual Spectrum

Ertapenem is indicated ONLY for carbapenem-susceptible Enterobacteriaceae, including susceptible K. pneumoniae 6, 1. The 2019 Taiwan pneumonia guidelines note that ertapenem 1g daily was equivalent to ceftriaxone for community-acquired pneumonia due to susceptible Enterobacteriaceae including Klebsiella species 6.

Critical Clinical Pitfall

Using ertapenem for suspected or confirmed carbapenem-resistant organisms or Enterococcus infections will result in:

  • Treatment failure
  • Increased mortality (approximately one in three patients with CRKP die even with appropriate therapy 2)
  • Delayed appropriate therapy, which significantly worsens outcomes 2

When carbapenem resistance is suspected or confirmed, rapid carbapenemase testing should be performed immediately to guide selection of novel β-lactam/β-lactamase inhibitor combinations 2. Time from blood culture to active antibiotic therapy directly influences mortality in critically ill patients with CRKP 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.